Cell Therapeutics CEO Unloads $142,000 in Stock (CTIC)
Cell Therapeutics (NASDAQ:CTIC) CEO James A. Bianco unloaded 50,000 shares of the stock on the open market in a transaction that occurred on Friday, June 27th. The stock was sold at an average price of $2.84, for a total value of $142,000.00. Following the completion of the sale, the chief executive officer now directly owns 2,297,794 shares in the company, valued at approximately $6,525,735. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Cell Therapeutics (NASDAQ:CTIC) traded down 1.04% on Friday, hitting $2.86. 1,270,172 shares of the company’s stock traded hands. Cell Therapeutics has a one year low of $0.97 and a one year high of $4.25. The stock has a 50-day moving average of $2.91 and a 200-day moving average of $3.05. The company’s market cap is $406.5 million. Cell Therapeutics also was the target of a significant growth in short interest in June. As of June 13th, there was short interest totalling 12,847,530 shares, a growth of 29.6% from the May 30th total of 9,913,697 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average daily volume of 1,917,297 shares, the short-interest ratio is presently 6.7 days.
Cell Therapeutics (NASDAQ:CTIC) last issued its quarterly earnings data on Tuesday, April 29th. The company reported ($0.20) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.17) by $0.03. The company had revenue of $1.40 million for the quarter, compared to the consensus estimate of $1.10 million. Analysts expect that Cell Therapeutics will post $-0.60 EPS for the current fiscal year.
Separately, analysts at Ladenburg Thalmann initiated coverage on shares of Cell Therapeutics in a research note on Thursday, May 22nd. They set a “buy” rating and a $6.00 price target on the stock. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Cell Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $4.83.
Cell Therapeutics, Inc develops, acquires and commercializes treatments for cancer. It focuses on building a biopharmaceutical company with a diversified portfolio of oncology drugs.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.